Stub Period Comparative Data (Unaudited) (Tables)

6 Months Ended

Dec. 31, 2016

Stub Period Comparative Data (Unaudited)

Condensed consolidated statement of earnings

	Six Months Ended
	December 31,
	2015
Revenues:
License and milestone fees	$	16,762
Royalty revenue		195
Non-cash royalty revenue related to the sale of future royalties		11,975
Research and development support		1,620
Clinical materials revenue		2,328
Total revenues		32,880
Operating Expenses:
Research and development		73,331
General and administrative		16,383
Total operating expenses		89,714
Loss from operations		(56,834)
Investment income, net		111
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes		(10,202)
Interest expense on convertible senior notes		—
Other expense, net		(42)
Net loss	$	(66,967)
Basic and diluted net loss per common share	$	(0.77)